<DOC>
	<DOCNO>NCT00107614</DOCNO>
	<brief_summary>The purpose study find response side effect chemotherapy use combination drug call D.T . PACE ( Dexamethasone , Thalidomide , cis-Platinum , Adriamycin , Cyclophosphamide , Etoposide ) + Rituxan , follow two autologous transplant .</brief_summary>
	<brief_title>DT PACE , Tandem Autologous Transplant , Maintenance Therapy Waldenstrom 's Macroglobulinemia Patients</brief_title>
	<detailed_description>Approximately 25 patient , male female , age 18 old , regardless race ethnicity , participate study UAMS ( University Arkansas Medical Sciences ) . Participants receive two course chemotherapy regimen call DT PACE + Rituxan . This regimen consist 6 drug : Dexamethasone , Thalidomide , cis-Platinum , Adriamycin , Cyclophosphamide , Etoposide .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients must pathological diagnosis Waldenstrom 's Macroglobulinemia , advance and/or symptomatic disease require therapy . At least one follow must true : *Presence cytopenia , define Hemoglobin &lt; 11 gm % , WBC &lt; 2000/µl , platelet &lt; 100,000 µl ; *Presence extensive ( &gt; 3 cm ) symptomatic lymphadenopathy hepatosplenomegaly ; *Presence B symptom ( night sweat , fever , weight loss &gt; 10 % baseline ) ; *Presence severe neuropathy , otherwise explain ; *Progressive disease ( increase `` M '' &gt; 50 % observe , decrease hemoglobin &gt; 2 gm % , and/or decrease platelet &gt; 50,000/µl , and/or increase lymphadenopathy ) ; *Serum albumin &lt; 2.5 gm % ; *Persistently elevate β2M &gt; 3.0 absence renal impairment active infection . Hyperviscosity treat ( addition plasmapheresis ) presence All necessary baseline study determine eligibility must obtain within 35 day prior registration . Patients must performance status 02 base SWOG criterion . Patients poor performance status ( 34 ) , base solely bone pain , eligible . Patients must significant comorbid medical condition uncontrolled life threaten infection . Patients recent ( &lt; 6 month ) myocardial infarction , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control cardiac arrythmias ineligible . Ejection fraction ECHO must &gt; 50 % must perform within 60 day prior registration , unless patient receive chemotherapy within period time ( dexamethasone thalidomide exclude ) , case LVEF must repeat . Patients must creatinine &lt; 3 mg/dl creatinine clearance &gt; 30 ml/minute . Patients creatinine clearance 3050 ml receive 50 % cisplatin dose . Patients must adequate hepatic function define serum transaminase &lt; 2 x ULN direct bilirubin &lt; 2.0 mg/dl . Patients must able receive full dos DT PACE , opinion treat investigator , exception : *Patients receive prior adriamycin &gt; 450 mg/m2 LVEF &lt; 55 % . Adriamycin omit patient ; *Patients creatinine clearance 30 50 ml/minute , receive 50 % cisplatin dose . Patients must history chronic obstructive chronic restrictive pulmonary disease . Patients must adequate pulmonary function study &gt; 50 % predict mechanical aspect ( FEV1 , FVC , etc ) diffusion capacity ( DLCO ) &gt; 50 % predict . Patients unable complete pulmonary function test due myeloma related pain fracture must high resolution CT scan chest must also acceptable arterial blood gas define PO2 great 70 . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free least three year . Prior malignancy acceptable provide evidence disease within threeyear interval . Pregnant nursing woman may participate . Women childbearing potential must negative pregnancy test document within one week registration . Women/men reproductive potential may participate unless agree use effective contraceptive method . All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Waldenstrom</keyword>
</DOC>